Home Education and Events Small Airways Disease

The Hidden Risk of Small Airways Disease¹⁻²

The Hidden Risk of Small Airways Disease¹⁻²

Explore the hidden risk of small airways disease,1-2 and how our extrafine formulation portfolio can help reach and treat both the large and small airways.3-19

Explore videos

Discover more videos on a variety of respiratory topics.

  • From multiple to single inhaler triple therapy: simplifying COPD care

    From multiple to single inhaler triple therapy: simplifying COPD care

    Sarah Rust

    Sarah Rust explains the importance of simplifying COPD treatment by reducing the number of inhalers patients use.

    UK-RES-2501622 November 2025
  • Medium strength triple therapy in adult asthma

    Medium strength triple therapy in adult asthma

    Professor Dave Singh

    Dave Singh discusses the role of medium strength triple therapy in asthma.

    UK-RES-2501622 November 2025
  • Moving from ICS/LABA to single inhaler triple therapy in COPD

    Moving from ICS/LABA to single inhaler triple therapy in COPD

    Dr Neil Greening

    Dr Neil Greening discusses the shift in COPD management from ICS/LABA to single inhaler triple therapy.

    UK-RES-2501622 November 2025
View all resources

Talk to us

Request a call or meeting with your local Chiesi representative at a time which suits you.

Request now

Order training inhalers

Support your patients with their inhaler technique by ordering placebo training inhalers directly from Chiesi.

Order now

Sign up for updates

Want to hear more from Chiesi? Opt-in to receive updates on Chiesi Air products and services.

Sign up
UK-RES-2102745 - May 2022

References

  1. Usmani OS, et al. Mayo Clin Proc. 2021; 96(9): 2448–2463.
  2. Hasan A, et al. Lung India. 2021; 38(4): 350–358.
  3. De Backer J, et al. J Aerosol Med Pulm Drug Deliv. 2015; 28(2): 88–99.
  4. Scichilone N, et al. J Asthma Allergy. 2013; 6: 11–21.
  5. Trimbow pMDI 87/5/9 Summary of Product Characteristics. Chiesi Limited.
  6. Trimbow pMDI 172/5/9 Summary of Product Characteristics. Chiesi Limited.
  7. Trimbow NEXThaler 88/5/9 Summary of Product Characteristics. Chiesi Limited.
  8. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
  9. Fostair pMDI 200/6 Summary of Product Characteristics. Chiesi Limited.
  10. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
  11. Fostair NEXThaler 200/6 Summary of Product Characteristics. Chiesi Limited.
  12. Vos W, et al. Respiration. 2013; 86(5): 393–401.
  13. Carpagnano GE, et al. J Clin Med. 2024; 13(8): 2320.
  14. Baldi S, et al. CHEST. 2020; 158(4S): 1664A.
  15. Gogali A, et al. Int J Chron Obstruct Pulmon Dis. 2025; 20: 1651–1663.
  16. Usmani OS, et al. J Aerosol Med Pulm Drug Deliv. 2022; 35(4): 179–185.
  17.  Usmani OS, et al. Int J Chron Obstruct Pulmon Dis. 2020; 15: 2433–2440.
  18.  De Backer W, et al. J Aerosol Med Pulm Drug Deliv. 2010; 23(3): 137–148.
  19. Virchow JC, et al. J Aerosol Med Pulm Drug Deliv. 2018; 31(5): 269–280.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.